EQRX EQRX INC

EQRx to Hold Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022

EQRx to Hold Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022

CAMBRIDGE, Mass., Oct. 28, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substantially lower prices, today announced it will host a conference call and webcast on Thursday, November 10, 2022 at 8:00 a.m. ET to report its third quarter 2022 financial results and provide a business update.

A live webcast of the call will be available on the “Investor Relations” page of the Company’s website at . To access the call by phone, participants should visit this link () to receive dial-in details. Participants are requested to register at least 15 minutes before the start of the call. The webcast will be made available for replay on the Company’s website beginning approximately two hours after the event.

About EQRx

EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at substantially lower prices. Launched in January 2020, EQRx is purpose-built, at scale, with a growing catalog of medicines in development in high-cost drug categories and emerging partnerships with leading payers and health systems. Leveraging cutting-edge science and technology and strategic partnerships with stakeholders from across the healthcare system, EQRx aims to provide innovative, patent-protected medicines more efficiently and cost-effectively than ever before. To learn more, visit and follow us on social media: Twitter: , , Instagram: .

EQRx™ and Remaking Medicine™ are trademarks of EQRx.

EQRx Contacts:

Media:

Dan Budwick

1AB

Investors:



EN
28/10/2022

Underlying

EQRXEQRX INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on EQRX INC

 PRESS RELEASE
Free
EQRX EQRX INC

EQRx Resets to Focus on Clinically Differentiated Medicines, Leveragin...

EQRx Resets to Focus on Clinically Differentiated Medicines, Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results Company to utilize significant scale of capital and team to advance a pipeline of clinically differentiated, high-value therapiesPrioritizing development of lerociclib (CDK 4/6 inhibitor); initiated Phase 3 trial in first-line advanced endometrial cancer; enrollment in Phase 2 trial in first- and second-line advanced breast cancer near completion, providing a foundation for future combination development opportunitiesSeeking commercialization partn...

May 8, 2023 1 EN
 PRESS RELEASE
Free
EQRX EQRX INC

EQRx to Hold First Quarter 2023 Financial Results Conference Call on M...

EQRx to Hold First Quarter 2023 Financial Results Conference Call on Monday, May 8, 2023 CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today announced it will host a conference call and webcast on Monday, May 8, 2023, at 4:30 p.m. ET to report its first quarter 2023 financial results and provide a business update. A live webcast of the call will be available on t...

April 27, 2023 1 EN
 PRESS RELEASE
Free
EQRX EQRX INC

EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and R...

EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress For Investors Lerociclib: Ongoing Phase 2 trial in first- and second-line treatment of metastatic breast cancer; expect to initiate Phase 3 trial in advanced endometrial cancer in 1H 2023 Aumolertinib: MAAs accepted for review by MHRA and EMA for EGFR-mutated NSCLC Sugemalimab: MAAs accepted for review by MHRA and EMA for the first-line treatment of metastatic NSCLC in combination with chemotherapyEnded 2022 with $1.4 billion in cash, cash equivalents and short-term investments; anticipate run...

February 23, 2023 1 EN
 PRESS RELEASE
Free
EQRX EQRX INC

EQRx to Present at the 41st Annual J.P. Morgan Healthcare Conference

EQRx to Present at the 41st Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 4:30 p.m. PST / 7:30 p.m. EST. A live and archived webcast of the presentation will be available by visiting the News ...

January 3, 2023 1 EN
 PRESS RELEASE
Free
EQRX EQRX INC

EQRx Announces Acceptance of Marketing Authorization Application by th...

EQRx Announces Acceptance of Marketing Authorization Application by the UK’s Medicines and Healthcare Products Regulatory Agency for Sugemalimab in Metastatic Non-small Cell Lung Cancer Application is based on data from the pivotal Phase 3 GEMSTONE-302 trial assessing sugemalimab in combination with chemotherapy as first-line treatment of metastatic non-small cell lung cancerAcceptance of the marketing authorization application (MAA) is EQRx’s second from the United Kingdom’s Medicines and Healthcare products Regulatory Agency after acceptance of aumolertinib MAA earlier this year CAMBRI...

December 19, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch